Access to the right medicines is an important component in managing arthritis. In Canada, the Patented Medicines Prices Review Board (PMPRB) plays a key role in drug pricing in Canada. On July 1, 2020, the newly amended Patented Medicines Regulations will come into force. To implement those amendments, the PMPRB consulted stakeholders and the public on proposed changes to its pricing Guidelines. CAPA provided written feedback as part of this consultation process. We believe that the patient community has an important voice based on their lived experiences with arthritis. Please click here to read our letter.